 In North America and Europe, Atripla is marketed jointly by Gilead Sciences and Bristol-Myers Squibb, but in much of the developing world, marketing and distribution is handled by Merck & Co.The wholesale cost in the developing world is about US$10.71–14.19 per month as of 2014.Atripla is a pink, film-coated tablet with "123" impressed on one side.